secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001437749-25-002160
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals secures $8.9M financing from Anson Funds to support NDA filings, operations into 2026
--------------------------------------------------------------------------------

- Issued $5.435M senior secured notes (net proceeds ~$5M) and warrants for 862,699 shares at $3.78 strike; registered direct offering of 1,215,278 shares at $2.88/share.
- Total gross proceeds of ~$8.9M from Anson Funds; notes carry 8% OID, 6% interest, 15-month maturity, convertible at $3.78/share subject to reset.
- Proceeds will fund NRX-100 and NRX-101 NDA filings, HOPE Therapeutics launch, and potential pipeline additions; expected to fund operations into 2026.
- Company believes combined with projected sales and non-dilutive funding it can reach profitability; includes waiver of certain investor rights through March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/0001437749-25-002160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/nrxp20250128_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-002160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer